Summit Therapeutics (SMMT) Appoints Alessandra Cesano to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- S&P 500 ends higher as traders shift from AI to healthcare
- Caterpillar names Derrick York to lead Resource Industries
- Most Asian stocks rise as calm returns after CoreWeave shock; Indonesia faces market downgrade
Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors
November 17, 2022 4:15 PM ESTMenlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately.
Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs, stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our... More



